Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Total Liabilities (2022 - 2025)

Historic Total Liabilities for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $8.7 million.

  • Corvus Pharmaceuticals' Total Liabilities fell 8123.95% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year decrease of 8123.95%. This contributed to the annual value of $36.3 million for FY2024, which is 42902.9% up from last year.
  • As of Q3 2025, Corvus Pharmaceuticals' Total Liabilities stood at $8.7 million, which was down 8123.95% from $9.2 million recorded in Q2 2025.
  • In the past 5 years, Corvus Pharmaceuticals' Total Liabilities registered a high of $46.4 million during Q3 2024, and its lowest value of $6.7 million during Q1 2024.
  • For the 4-year period, Corvus Pharmaceuticals' Total Liabilities averaged around $14.3 million, with its median value being $10.1 million (2025).
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 50637.66% in 2024, then crashed by 8123.95% in 2025.
  • Over the past 4 years, Corvus Pharmaceuticals' Total Liabilities (Quarter) stood at $12.1 million in 2022, then crashed by 43.35% to $6.9 million in 2023, then skyrocketed by 429.03% to $36.3 million in 2024, then crashed by 76.04% to $8.7 million in 2025.
  • Its last three reported values are $8.7 million in Q3 2025, $9.2 million for Q2 2025, and $10.1 million during Q1 2025.